Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Arch Biopartners Closes Convertible Note Financing

Posted on: 16 Feb 18

TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX-V:ARCH) (OTCBB:ACHFF) announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it announced in a press release February 8, 2018 for gross proceeds of CAD $600,000 (the “Offering”).

The Note matures on February 28, 2021 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $0.60, in the thirty-day period prior to maturity of the Note.

The Note bears simple interest of 5% per annum, which is payable in-kind by the Company with Common Shares to be issued at then market prices for the Common Shares and subject to TSX Venture Exchange (“TSXV”) approval in each instance.

The holder has the option until November 30, 2020 to extend the term of the Note another 2 years to February 28, 2023.

All securities to be issued in connection with the Offering will be subject to a statutory hold period of four months from the time of issuance.

The Offering is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including Final Approval of the TSXV, which previously granted Conditional Approval of the Offering. There were no finder's fees paid in connection with the Offering.

On February 2, 2018, the Company also closed the first $625,000 tranche of the non brokered private placement announced in a press release January 26, 2018 (the “Common Shares Offering”). Pursuant to the Common Shares Offering, Arch issued 1,250,000 common shares priced at $0.50 per common share (the “Units”) for gross proceeds of $625,000.  A second tranche of $625,000 is expected to close on March 10, 2018. All securities issued in connection with the Common Shares Offering are subject to a hold period of four months and one day from the closing date. There were no finder's fees paid in connection with the Common Shares Offering.

The Company will use the proceeds to continue funding the ongoing preclinical development of Metablok and the ongoing clinical development of AB569 during 2018.  Metablok is the Company’s drug candidate for inhibiting acute kidney injury, septic shock and cancer metastasis. AB569 is the Company’s inhalation drug candidate for treating antibiotic-resistant bacterial infections in the lungs of patients with chronic obstructive pulmonary disease or cystic fibrosis, as well as many other indications.

There is no material fact or material change about the Company that has not been generally disclosed.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.

Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; Metablok, a potential treatment for inflammation, sepsis and cancer metastasis; MetaMx, which targets elusive brain tumor initiating cells; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit

The Company has 56,549,679 common shares outstanding.

For more information, please contact:

Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Last updated on: 20/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.